PresentationPDF Available

Modelling the late effects of cancer treatment on the ovary

Authors:

Abstract and Figures

Invited Keynote Presentation
No caption available
… 
No caption available
… 
No caption available
… 
No caption available
… 
No caption available
… 
Content may be subject to copyright.
University*of*St*Andrews1
School*of*Computer*Science1
Modelling the late effects of
cancer treatment on the ovary
Edinburgh Fertility 2016
Tom$Kelsey$
School*of*Computer*Science1
Overview
!"#$%&'"(')*$'*$+%)*,'
-"-.%+/"0'
0"0123"4502'("%%56%$&'
"7+35+0'7"%.8$'''
!"#$%'7+%5#+/"0'
9&$'"(')*$'8"#$%&')"'
-3$#56):;.+0/(,:
$&/8+)$'%+)$'$<$6)&'
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
='
D;.+/"0&'
G)+/&/6&'
-17+%.$&'
H"33$%+/"0'6"$I65$0)&''
H"0J#$06$'50)$37+%&''''
K$357+/"0'#$)+5%&'
F.0#502'%"2"&'
L*")"&'"('6"%%$+2.$&'
''
School*of*Computer*Science1
Non-Growing Follicles
Ovarian reserve
Born with a population that declines until
menopause
NGFs are selected for maturation
Impossible to measure in vivo
Using current technologies
Populations are counted in vitro
Typically histological examination of stained
tissue
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
M'
School*of*Computer*Science1
NGFs – Wallace & Kelsey 2010
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
N'
=>)*'?.0$'=>@A'
O+%%+6$'OPQ'C$%&$,'BOR''
P.8+0'"7+35+0'3$&$37$'(3"8'6"06$-/"0')"')*$'8$0"-+.&$R'
LS"G'TUDR'=>@>VWX@YZ$[\\=R'
School*of*Computer*Science1
NGFs – Wallace & Kelsey 2010
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
W'
=>)*'?.0$'=>@A'
School*of*Computer*Science1
Ovarian Volume
Indirect measure of ovarian reserve
Possible to measure in vivo
2D & 3D ultrasound
The assumption is that a large ovary
contains more NGFs than a small one
Clearly true when comparing pre- and post-
menopausal ovaries
We have no evidence for this assumption for
pre-menopausal ages
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
A'
School*of*Computer*Science1 B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
\'
=>)*'?.0$'=>@A'
C$%&$,'BOQ'K"#4$%%'GCQ'et$alR''
T7+35+0'7"%.8$')*3".2*".)'%5($Z'+'7+%5#+)$#'0"38+/7$'8"#$%R''
LS"G'TUDR'=>@MV[X]YZ$\@NAW''
School*of*Computer*Science1
Model Validation
O$'internally)validate'8"#$%&'E$("3$'
&.E85&&5"0'("3'3$75$4'
H+3$(.%'6*$6^&')*+)')*$'E$&)'8"#$%'5&0_)'E+&$#'"0'
+'6*+06$'6"0J2.3+/"0'"(')*$'#+)+'
`#$+%%,Q'4$'4+0)'external)valida-on)
H"8-+35&"0'"('".3'-3$#56/"0&')"'"E&$37+/"0&'
8+#$'+)'+'%+)$3'#+)$'RRR'
RRR'+0#'50'+0")*$3'%+E''
`('"E&$37+/"0&'+3$'6%"&$')"'-3$#56/"0&Q')*$'
-3$#56/7$'8"#$%'5&'+'.&$(.%'2.5#$')"'0"38+%'
7+%.$&'a'3+02$&'
5('0")Q'5)_&'E+6^')"')*$'#3+4502'E"+3#'
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
['
School*of*Computer*Science1 =>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
]'
K$-8+00'!Q'F+##,'
!?Q'et$alR''
B*$'3$%+/"0'
E$)4$$0'7+35+/"0'
50'&5b$'"(')*$'
-358"3#5+%'("%%56%$'
-""%'+0#'+2$'+)'
0+).3+%'8$0"-+.&$''
?'H%50'D0#"6350"%'
!$)+E'=>@WV@>>XAY'
TE&$37$#'
50'=>@W'
L3$#56)$#'
50'=>@>'
School*of*Computer*Science1 =>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@>'
!6S+.2*%50'!Q'C$%&$,'BOQ'et$alR'
c0'$d)$30+%%,'7+%5#+)$#'+2$13$%+)$#'8"#$%'"('8$+0'("%%56%$'#$0&5),'50')*$'6"3)$d'"(')*$'*.8+0'
"7+3,R'?'c&&5&)'e$-'f$0R'=>@WVM=X\YZ@>[]1]WR'
Using the models to assess infertility
=>)*'?.0$'=>@A'B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@@'
O$'*+7$'$d)$30+%'7+%5#+/"0Q'+0#'+'6"0/0.".&'
$0#$+7"3')"'58-3"7$'8"#$%&'+&'0$4'#+)+'
E$6"8$'+7+5%+E%$'
c%&"'g.&/(,502:)$&/02')*$'50*$3$0)'+&&.8-/"0&''
O$'0"4')+^$')*$'8"#$%&'+&'+'E+&$1%50$'
e$-3$&$0/02')*$'-"-.%+/"0'+h$3'b$3"1#"&$'
`('4$'^0"4'+2$'+)'LT`'+h$3'^0"40'#"&$&'RRR''
RRR'c0#:"3'5('4$'^0"4'!FK'+h$3')3$+)8$0)'
O$'6+0'$&/8+)$')*$'#+8+2$'#"0$')"')*$'
"7+35+0'3$&$37$'E,')*$')3$+)8$0)'
Using the models to assess infertility
=>)*'?.0$'=>@A'B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@='
Predicting POI after radiotherapy
=>)*'?.0$'=>@A'B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@M'
c0#$3&"0'ecQ'!5)6*$%%'eBQ'C$%&$,'BOQ'G-$+3&'UQ'B$%($3'DDQ'O+%%+6$'OPR''
H+06$3')3$+)8$0)'+0#'2"0+#+%'(.06/"0Z'$d-$358$0)+%'+0#'$&)+E%5&*$#'&)3+)$25$&'("3'($3/%5),'
-3$&$37+/"0'50'6*5%#3$0'+0#',".02'+#.%)&R'
S+06$)'K5+E$)$&'D0#"6350"%R'=>@WVMX\YZWWA1A\R'
=>)*'?.0$'=>@A'B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@N'
c0#$3&"0'ecQ'!5)6*$%%'eBQ'C$%&$,'BOQ'G-$+3&'UQ'B$%($3'DDQ'O+%%+6$'OPiR''
H+06$3')3$+)8$0)'+0#'2"0+#+%'(.06/"0Z'$d-$358$0)+%'+0#'$&)+E%5&*$#'&)3+)$25$&'("3'($3/%5),'
-3$&$37+/"0'50'6*5%#3$0'+0#',".02'+#.%)&R'
S+06$)'K5+E$)$&'D0#"6350"%R'=>@WVMX\YZWWA1A\R'
Effective Sterilising Doses
=>)*'?.0$'=>@A'B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@W'
!6S+.2*%50'!Q'C$%&$,'BOQ'O+%%+6$'OPiQ'c0#$3&"0'ecQ'B$%($3'DDR''
U"0123"4502'("%%56%$'#$0&5),'5&'5063$+&$#'("%%"4502'cijK'6*$8")*$3+-,'50')*$'+#.%)'*.8+0'
"7+3,R'
K+)+'0")'-.E%5&*$#'
School*of*Computer*Science1
Summary
UfF&'+0#'"7+35+0'7"%.8$&'50)3"#.6$#'*$3$'
T)*$3'8"#$%&'*+7$'E$$0'#$357$#Q'7+%5#+)$#'a'-.E%5&*$#'
9)$350$'7"%.8$@Q'50*5E50'i'X8+%$&Y=Q')$&)"&)$3"0$'X8+%$&YMQ'
c!PQ'RRR'
T)*$3'+--%56+/"0&'*+7$'E$$0'-.E%5&*$#'
LHTGQ'E3$+&)'6+06$3NQ'`jFQ'#5+E$)$&WQ'RRR'
D+6*'5&'+'8.%/1#5&65-%50+3,'$<"3)')"'5#$0/(,Q'6"%%$6)'a'
+0+%,&$'#+)+'
T.3'"40Q'+0#'#+)+'-.E%5&*$#'E,'")*$3&'
F"%%"4$#'E,'8"#$%'#$357+/"0Q'&$%$6/"0'a'X%$7$%&'"(Y'
7+%5#+/"0'
T.3'+58'5&'.&$(.%'+0#'+66.3+)$';.+0/J6+/"0'"(')*$'
$<$6)&'"(')3$+)8$0)X&Y'"0')*$'($3/%5),'"('&.3757"3&'"('
6+06$3'
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@A'
School*of*Computer*Science1
References
@RC$%&$,Q'BR'ORQ'f50E$,Q'DRQ'$)'+%R'X=>@AYR'c'j+%5#+)$#'
U"38+/7$'!"#$%'("3'P.8+0'9)$350$'j"%.8$'(3"8'i53)*'
)"'c2$'N>'k$+3&R'PloS$one,$6,'$>@W\M\WR'
=RC$%&$,Q'BR'ORQ'!5%$&Q'cRQ'$)'+%R'X=>@AYR'c'U"38+/7$'!"#$%'
"('G$3.8'`0*5E50'i'50'k".02'!+%$&R'PloS$one,$4,'$>@WM[NMR'
MRC$%&$,Q'BR'ORQ'S5Q'SR'lRQ'$)'+%R'X=>@NYR'c'7+%5#+)$#'+2$1
3$%+)$#'0"38+/7$'8"#$%'("3'8+%$')")+%')$&)"&)$3"0$'
&*"4&'5063$+&502'7+35+06$'E.)'0"'#$6%50$'+h$3'+2$'N>'
,$+3&R'PloS$one,$10,'$@>]MNAR'
NRL*5%%5-&Q'CR'cRQ'H"%%50&Q'`R'!RQ'$)'+%R'X=>@AYR'c0/1!.%%$35+0'
*"38"0$'&$3.8'6"06$0)3+/"0&'"('4"8$0'45)*'2$38%50$'
ieHc@'"3'ieHc='8.)+/"0&R'Human$reproduc:on,$5,'
@@=Am@@M=R'
WR`%5"#3"85/Q'GRQ'G+&&+3505Q'?RQ'$)'+%R''X=>@AYR'c66.3+6,'"('
6536.%+/02'+#5-"0$6/0'("3'-3$#56/02'2$&)+/"0+%'#5+E$)$&Z'
+'&,&)$8+/6'3$75$4'+0#'8$)+1+0+%,&5&R'Diabetologia,$4,'
A]=mA]]R'
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@\'
School*of*Computer*Science1
Thank You
'
c0,';.$&/"0&n'
=>)*'?.0$'=>@A'
B"8'C$%&$,'1'D#50E.32*'F$3/%5),''
@['
ResearchGate has not been able to resolve any citations for this publication.
Article
Full-text available
Transabdominal pelvic ultrasound and/or pelvic Magnetic Resonance Imaging are safe, accurate and non-invasive means of determining the size and configuration of the internal female genitalia. The assessment of uterine size and volume is helpful in the assessment of many conditions including disorders of sex development, precocious or delayed puberty, infertility and menstrual disorders. Using our own data from the assessment of MRI scans in healthy young females and data extracted from four studies that assessed uterine volume using transabdominal ultrasound in healthy females we have derived and validated a normative model of uterine volume from birth to age 40 years. This shows that uterine volume increases across childhood, with a faster increase in adolescence reflecting the influence of puberty, followed by a slow but progressive rise during adult life. The model suggests that around 84% of the variation in uterine volumes in the healthy population up to age 40 is due to age alone. The derivation of a validated normative model for uterine volume from birth to age 40 years has important clinical applications by providing age-related reference values for uterine volume.
Article
Full-text available
Inhibin B has been identified as a potential marker of Sertoli cell function in males. The aim of this study is to produce a normative model of serum inhibin B in males from birth to seventeen years. We used a well-defined search strategy to identify studies containing data that can contribute to a larger approximation of the healthy population. We combined data from four published studies (n = 709) and derived an internally validated model with high goodness-of-fit and normally distributed residuals. Our results show that inhibin B increases following birth to a post-natal peak of 270 pg/mL (IQR 210-335 pg/mL) and then decreases during childhood followed by a rise at around 8 years, peaking at a mean 305 pg/mL (IQR 240-445 pg/mL) at around age 17. Following this peak there is a slow decline to the standard mature adult normal range of 170 pg/mL (IQR 125-215 pg/mL). This normative model suggests that 35% of the variation in Inhibin B levels in young males is due to age alone, provides an age-specific reference range for inhibin B in the young healthy male population, and will be a powerful tool in evaluating the potential of inhibin B as a marker of Sertoli cell function in pre-pubertal boys.
Article
Full-text available
Preservation of gonadal function is an important priority for the long-term health of cancer survivors of both sexes and all ages at treatment. Loss of opportunity for fertility is a prime concern in both male and female cancer survivors, but endocrine effects of gonadal damage are likewise central to long-term health and wellbeing. Some fertility preservation techniques, such as semen and embryo cryopreservation, are established and successful in adults, and development of oocyte vitrification has greatly improved the potential to cryopreserve unfertilised oocytes. Despite being recommended for all pubertal male patients, sperm banking is not universally practised in paediatric oncology centres, and very few adolescent-friendly facilities exist. All approaches to fertility preservation have specific challenges in children and teenagers, including ethical, practical, and scientific issues. For young women, cryopreservation of ovarian cortical tissue with later replacement has resulted in at least 40 livebirths, but is still regarded as experimental in most countries. For prepubertal boys, testicular biopsy cryopreservation is offered in some centres, but how that tissue might be used in the future is unclear, and so far no evidence suggests that fertility can be restored. For both sexes, these approaches involve an invasive procedure and have an uncertain risk of tissue contamination in haematological and other malignancies. Decision making for all these approaches needs assessment of the individual's risk of fertility loss, and is made at a time of emotional distress. Development of this specialty needs better provision of information for patients and their medical teams, and improvements in service provision, to match technical and scientific advances. Copyright © 2015 Elsevier Ltd. All rights reserved.
Article
Full-text available
The diagnosis of hypogonadism in human males includes identification of low serum testosterone levels, and hence there is an underlying assumption that normal ranges of testosterone for the healthy population are known for all ages. However, to our knowledge, no such reference model exists in the literature, and hence the availability of an applicable biochemical reference range would be helpful for the clinical assessment of hypogonadal men. In this study, using model selection and validation analysis of data identified and extracted from thirteen studies, we derive and validate a normative model of total testosterone across the lifespan in healthy men. We show that total testosterone peaks [mean (2.5-97.5 percentile)] at 15.4 (7.2-31.1) nmol/L at an average age of 19 years, and falls in the average case [mean (2.5-97.5 percentile)] to 13.0 (6.6-25.3) nmol/L by age 40 years, but we find no evidence for a further fall in mean total testosterone with increasing age through to old age. However we do show that there is an increased variation in total testosterone levels with advancing age after age 40 years. This model provides the age related reference ranges needed to support research and clinical decision making in males who have symptoms that may be due to hypogonadism.
Article
Increased risks of female breast cancer, ovarian cancer, fallopian tube cancer, and primary peritoneal cancer have been attributed to germline mutations in the BRCA1 or BRCA2 genes. These also have an impact on ovarian reserve and fertility in women.
Article
Inhibin B has been identified as a potential marker of Sertoli cell function in males. The aim of this study is to produce a normative model of serum inhibin B in males from birth to seventeen years. We used a well-defined search strategy to identify studies containing data that can contribute to a larger approximation of the healthy population. We combined data from four published studies (n = 709) and derived an internally validated model with high goodness of fit and normally distributed residuals. Our results show that inhibin B increases following birth to a post-natal peak of 270 pg/mL (IQR 210–335 pg/mL) and then decreases during childhood followed by a rise at around 8 years, peaking at a mean 305 pg/mL (IQR 240–445 pg/mL) at around age 17. Following this peak there is a slow decline to the standard mature adult normal range of 170 pg/mL (IQR 125–215 pg/mL). This normative model suggests that 35% of the variation in Inhibin B levels in young males is due to age alone, provides an age-specific reference range for inhibin B in the young healthy male population, and will be a powerful tool in evaluating the potential of inhibin B as a marker of Sertoli cell function in pre-pubertal boys.